|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
ELV039310329 |
| 003 |
DE-627 |
| 005 |
20230625224616.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
180603s2014 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.pcd.2013.09.003
|2 doi
|
| 028 |
5 |
2 |
|a GBVA2014009000007.pica
|
| 035 |
|
|
|a (DE-627)ELV039310329
|
| 035 |
|
|
|a (ELSEVIER)S1751-9918(13)00114-9
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
4 |
|a 610
|q DE-600
|
| 082 |
0 |
4 |
|a 630
|q VZ
|
| 082 |
0 |
4 |
|a 640
|q VZ
|
| 082 |
0 |
4 |
|a 590
|q VZ
|
| 082 |
0 |
4 |
|a 610
|q VZ
|
| 082 |
0 |
4 |
|a 600
|q VZ
|
| 084 |
|
|
|a 50.70
|2 bkl
|
| 100 |
1 |
|
|a Khunti, Kamlesh
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Insulin degludec – The impact of a new basal insulin on care in type 2 diabetes
|
| 264 |
|
1 |
|c 2014transfer abstract
|
| 300 |
|
|
|a 7
|
| 336 |
|
|
|a nicht spezifiziert
|b zzz
|2 rdacontent
|
| 337 |
|
|
|a nicht spezifiziert
|b z
|2 rdamedia
|
| 338 |
|
|
|a nicht spezifiziert
|b zu
|2 rdacarrier
|
| 520 |
|
|
|a Many patients with type 2 diabetes continue to have poor glycaemic control and would benefit from insulin therapy. However, resistance to the introduction of insulin therapy can be high on both the part of the healthcare provider and the patient. A number of new, long-acting basal insulins are in development that provide good metabolic control, but with a lower risk of hypoglycaemia than currently available insulins, and greater flexibility in dosing time from day to day. These attributes may address some of the current barriers to insulin initiation and intensification that currently limit the effectiveness of diabetes care.
|
| 520 |
|
|
|a Many patients with type 2 diabetes continue to have poor glycaemic control and would benefit from insulin therapy. However, resistance to the introduction of insulin therapy can be high on both the part of the healthcare provider and the patient. A number of new, long-acting basal insulins are in development that provide good metabolic control, but with a lower risk of hypoglycaemia than currently available insulins, and greater flexibility in dosing time from day to day. These attributes may address some of the current barriers to insulin initiation and intensification that currently limit the effectiveness of diabetes care.
|
| 650 |
|
7 |
|a Diabetes
|2 Elsevier
|
| 700 |
1 |
|
|a Cos, Xavier
|4 oth
|
| 700 |
1 |
|
|a Rutten, Guy
|4 oth
|
| 773 |
0 |
8 |
|i Enthalten in
|n Elsevier
|a David, Lauren A. ELSEVIER
|t A pilot randomized controlled trial examining the feasibility, acceptability, and efficacy of Adapted Motivational Interviewing for post-operative bariatric surgery patients
|d 2016
|g Amsterdam [u.a.]
|w (DE-627)ELV024210129
|
| 773 |
1 |
8 |
|g volume:8
|g year:2014
|g number:2
|g pages:119-125
|g extent:7
|
| 856 |
4 |
0 |
|u https://doi.org/10.1016/j.pcd.2013.09.003
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_U
|
| 912 |
|
|
|a GBV_ELV
|
| 912 |
|
|
|a SYSFLAG_U
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_227
|
| 912 |
|
|
|a GBV_ILN_350
|
| 936 |
b |
k |
|a 50.70
|j Energie: Allgemeines
|q VZ
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 8
|j 2014
|e 2
|h 119-125
|g 7
|
| 953 |
|
|
|2 045F
|a 610
|